I-Mab announced its financial results for the first quarter ended March 31, 2025, reporting a cash and cash equivalents, and short-term investments balance of $168.6 million. This financial position is projected to fund the company's operations into 2027, covering expected clinical readouts for givastomig.
The company reiterated its prioritization of givastomig as its lead program, positioning I-Mab for continued clinical progress. This focus aligns with its strategy as a U.S.-based global biotech company dedicated to immuno-oncology.
Further supporting its lead program, new givastomig combination data has been selected for a mini-oral presentation at the European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO GI), scheduled for July 2-5, 2025, in Barcelona, Spain.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.